Muhammad Safiullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Safiullah has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Imaz Bhatti
King Edward Medical University
4 shared publications - Husam Abu Dawood
Palestine Polytechnic University
2 shared publications Muhammad Nabeel Saddique
King Edward Medical University
2 shared publications- Aashni Purohit1 shared publication
Abdullah Bin Amir
King Edward Medical University Lahore Pakistan
1 shared publication- Adnan Bhat
Division of Hospital Medicine, Department of Medicine, University of Florida, Gainesville, FL, USA
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Burden of Alzheimer's disease and associated risk factors in Pakistan versus other South Asian countries: Insights from the Global Burden of Disease Study 2021
Introduction: Pakistan's aging population and rising prevalence of metabolic and lifestyle risk factors have driven an increasing Alzheimer's disease and other dementias (ADOD) burden. This study provides comprehensive evaluation of ADOD burden in Pakistan over three decades. Objective: This study provides comprehensive evaluation of ADOD burden in Pakistan over three decades. Methods: We extracted province-level ADOD data from the Global Burden of Disease Study 2021. Joinpoint regression quantified average annual percent changes (AAPCs) with 95% confidence intervals (CIs). An autoregressive integrated moving average (ARIMA) model forecasted ADOD trends for the next 30 years. Results: In 2021, Pakistan ranked second in South Asia for ADOD burden. The age-standardized incidence rate declined from 84.44 (95% UI: [73.08–97.02]) in 1990 to 78.80 (67.99–90.38) in 2021 (AAPC −0.22%, 95% CI: [–0.22 to −0.22]). Meanwhile, age-standardized mortality and DALY rates rose (AAPCs 0.43%, 95% CI: [0.42–0.45]; and 0.22%, 95% CI: [0.21–0.23], respectively). Conclusions: Pronounced regional disparities and dominant metabolic risk factors underscore the urgent need for targeted prevention and intervention strategies to curb Pakistan's rising ADOD burden.
- 29 October 2026
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 10
Open AccessBurden of Alzheimer's disease and associated risk factors in Pakistan versus other South Asian countries: Insights from the Global Burden of Disease Study 2021
Introduction: Pakistan's aging population and rising prevalence of metabolic and lifestyle risk factors have driven an increasing Alzheimer's disease and other dementias (ADOD) burden. This study provides comprehensive evaluation of ADOD burden in Pakistan over three decades. Objective: This study provides comprehensive evaluation of ADOD burden in Pakistan over three decades. Methods: We extracted province-level ADOD data from the Global Burden of Disease Study 2021. Joinpoint regression quantified average annual percent changes (AAPCs) with 95% confidence intervals (CIs). An autoregressive integrated moving average (ARIMA) model forecasted ADOD trends for the next 30 years. Results: In 2021, Pakistan ranked second in South Asia for ADOD burden. The age-standardized incidence rate declined from 84.44 (95% UI: [73.08–97.02]) in 1990 to 78.80 (67.99–90.38) in 2021 (AAPC −0.22%, 95% CI: [–0.22 to −0.22]). Meanwhile, age-standardized mortality and DALY rates rose (AAPCs 0.43%, 95% CI: [0.42–0.45]; and 0.22%, 95% CI: [0.21–0.23], respectively). Conclusions: Pronounced regional disparities and dominant metabolic risk factors underscore the urgent need for targeted prevention and intervention strategies to curb Pakistan's rising ADOD burden.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
Pre‐Emptive TIPS for Acute Variceal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: There is evolving evidence regarding whether pre‐emptive transjugular intrahepatic portosystemic shunt (p‐TIPS) improves outcomes in patients with acute variceal bleeding. This meta‐analysis is aimed at evaluating the effectiveness of p‐TIPS compared with standard care in reducing mortality and rebleeding in high‐risk patients with cirrhosis. Methods: We systematically searched CENTRAL, MEDLINE, Embase, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) comparing p‐TIPS placed within 72 h of admission with standard care. All statistical analyses were performed using RevMan Version 5.4. Results: Six RCTs ( n = 424 participants) met inclusion criteria. p‐TIPS significantly reduced all‐cause mortality (RR 0.54, 95% CI 0.39–0.76; ARR 14.9%; NNT ≈ 7) and rebleeding (RR 0.29, 95% CI 0.16–0.55; ARR 28.4%; NNT ≈ 4) compared with standard care, with consistent effects across variceal subtypes and degrees of hepatic decompensation. p‐TIPS also significantly reduced new or worsening ascites (RR 0.51, 95% CI 0.35–0.74), hepatorenal syndrome (RR 0.37, 95% CI 0.15–0.92), liver‐related mortality (RR 0.56, 95% CI 0.34–0.94), and serious adverse events (RR 0.72, 95% CI 0.59–0.88), without increasing hepatic encephalopathy (RR 1.01, 95% CI 0.72–1.43). Conclusions: p‐TIPS significantly reduced mortality and rebleeding risk in high‐risk patients with acute variceal bleeding, without increasing encephalopathy risk. These findings support its broader integration into clinical practice guidelines. Further large‐scale RCTs with extended follow‐up are warranted to define optimal patient selection, particularly in gastric variceal subgroups. PROSPERO: CRD420261329675
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
Open AccessPre‐Emptive TIPS for Acute Variceal Bleeding: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Background: There is evolving evidence regarding whether pre‐emptive transjugular intrahepatic portosystemic shunt (p‐TIPS) improves outcomes in patients with acute variceal bleeding. This meta‐analysis is aimed at evaluating the effectiveness of p‐TIPS compared with standard care in reducing mortality and rebleeding in high‐risk patients with cirrhosis. Methods: We systematically searched CENTRAL, MEDLINE, Embase, and ClinicalTrials.gov to identify randomized controlled trials (RCTs) comparing p‐TIPS placed within 72 h of admission with standard care. All statistical analyses were performed using RevMan Version 5.4. Results: Six RCTs ( n = 424 participants) met inclusion criteria. p‐TIPS significantly reduced all‐cause mortality (RR 0.54, 95% CI 0.39–0.76; ARR 14.9%; NNT ≈ 7) and rebleeding (RR 0.29, 95% CI 0.16–0.55; ARR 28.4%; NNT ≈ 4) compared with standard care, with consistent effects across variceal subtypes and degrees of hepatic decompensation. p‐TIPS also significantly reduced new or worsening ascites (RR 0.51, 95% CI 0.35–0.74), hepatorenal syndrome (RR 0.37, 95% CI 0.15–0.92), liver‐related mortality (RR 0.56, 95% CI 0.34–0.94), and serious adverse events (RR 0.72, 95% CI 0.59–0.88), without increasing hepatic encephalopathy (RR 1.01, 95% CI 0.72–1.43). Conclusions: p‐TIPS significantly reduced mortality and rebleeding risk in high‐risk patients with acute variceal bleeding, without increasing encephalopathy risk. These findings support its broader integration into clinical practice guidelines. Further large‐scale RCTs with extended follow‐up are warranted to define optimal patient selection, particularly in gastric variceal subgroups. PROSPERO: CRD420261329675
- Open Access
- 26 November 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (6) , e70134
Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis
Background: Obesity represents a major global health challenge, contributing substantially to cardiovascular disease and metabolic complications. Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, has emerged as a promising therapeutic option for weight management and glycemic control. This meta‐analysis evaluated the efficacy and safety of orforglipron in obese patients with or without type 2 diabetes mellitus (T2DM). Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library and ClinicalTrials.gov from inception to October 2025 to identify randomised controlled trials (RCTs) evaluating orforglipron in obese patients. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Results: Five RCTs comprising 4410 participants were included. Orforglipron demonstrated dose‐dependent reductions in body weight from 2.48% at 3 mg to 9.8% at 45 mg, BMI from 0.89 to 3.62 kg/m 2 , waist circumference from 1.57 to 6.9 cm, and HbA1c from 0.76% to 1.04% compared with placebo. Favourable lipid changes included reductions in total cholesterol (MD: −4.51% [95% CI: −6.91 to −2.11]), LDL‐C (MD: −5.34% [95% CI: −7.10 to −3.58]), and triglycerides (MD: −10.07% [95% CI: −12.33 to −7.80]), with increased HDL‐C (MD: 2.94% [95% CI: 1.38 to 4.49]). However, gastrointestinal adverse events were significantly more frequent at doses of 12 mg or higher and treatment discontinuation rates were highest at 24 mg (RR:4.61 [95% CI:1.6 to 13.33]) and 36 mg (RR:3.68 [95% CI:2.48 to 5.44]) doses. Serious adverse events and mortality rates were comparable to those with placebo. Conclusion: Orforglipron significantly improved glycemic and lipid parameters in patients with obesity, demonstrating dose‐dependent efficacy with maximal benefits at higher doses. While gastrointestinal tolerability remains a clinically important limitation requiring mitigation strategies, orforglipron represents a promising oral therapeutic option for comprehensive obesity and metabolic management.
- 26 November 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (6) , e70134
Open AccessEfficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis
Background: Obesity represents a major global health challenge, contributing substantially to cardiovascular disease and metabolic complications. Orforglipron, a novel oral non‐peptide GLP‐1 receptor agonist, has emerged as a promising therapeutic option for weight management and glycemic control. This meta‐analysis evaluated the efficacy and safety of orforglipron in obese patients with or without type 2 diabetes mellitus (T2DM). Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library and ClinicalTrials.gov from inception to October 2025 to identify randomised controlled trials (RCTs) evaluating orforglipron in obese patients. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Results: Five RCTs comprising 4410 participants were included. Orforglipron demonstrated dose‐dependent reductions in body weight from 2.48% at 3 mg to 9.8% at 45 mg, BMI from 0.89 to 3.62 kg/m 2 , waist circumference from 1.57 to 6.9 cm, and HbA1c from 0.76% to 1.04% compared with placebo. Favourable lipid changes included reductions in total cholesterol (MD: −4.51% [95% CI: −6.91 to −2.11]), LDL‐C (MD: −5.34% [95% CI: −7.10 to −3.58]), and triglycerides (MD: −10.07% [95% CI: −12.33 to −7.80]), with increased HDL‐C (MD: 2.94% [95% CI: 1.38 to 4.49]). However, gastrointestinal adverse events were significantly more frequent at doses of 12 mg or higher and treatment discontinuation rates were highest at 24 mg (RR:4.61 [95% CI:1.6 to 13.33]) and 36 mg (RR:3.68 [95% CI:2.48 to 5.44]) doses. Serious adverse events and mortality rates were comparable to those with placebo. Conclusion: Orforglipron significantly improved glycemic and lipid parameters in patients with obesity, demonstrating dose‐dependent efficacy with maximal benefits at higher doses. While gastrointestinal tolerability remains a clinically important limitation requiring mitigation strategies, orforglipron represents a promising oral therapeutic option for comprehensive obesity and metabolic management.
- Open Access
Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta‐Analysis of Noninferiority Randomized Controlled Trials
Purpose: Proton pump inhibitors (PPIs) remain the standard treatment option for erosive esophagitis (EE) but have notable limitations due to side effects associated with long‐term use. Tegoprazan, a novel potassium‐competitive acid suppressant (P‐CAB), may provide an alternative treatment option. In this study, we aim to evaluate the healing rates of EE using tegoprazan versus PPIs, along with their respective safety profiles. Methods: A comprehensive literature search was conducted in PubMed, Embase, and ClinicalTrials.gov from inception to March 2025. Risk of bias was evaluated using the Cochrane RoB 2.0 tool. Pooled estimates were calculated using random‐effects models in Review Manager 5.4. Results: Three RCTs encompassing a total of 766 patients were included in the analysis. Tegoprazan demonstrated comparable healing rates to PPIs at both 4 weeks (risk ratio [RR] 1.05; 95% confidence interval [CI]: 0.99–1.11; p = 0.12) and 8 weeks (RR 1.02; 95% CI: 0.98–1.06; p = 0.35). Subgroup analyses by dose (50 and 100 mg) showed no significant differences. While overall adverse event rates were similar between groups, the incidence of headache was numerically lower in the tegoprazan group (1.3% vs. 4.2%; RR = 0.40; 95% CI: 0.08–2.00; p = 0.26), though this difference was not statistically significant. Conclusion: Tegoprazan shows comparable efficacy and safety to standard PPIs for treating EE. While healing rates were slightly higher, particularly with the 100 mg dose, the differences were not statistically significant. Tegoprazan may be a suitable alternative for patients intolerant to PPIs, though larger, long‐term, multiethnic studies are warranted to confirm these findings and assess patient‐centered outcomes.
Open AccessTegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta‐Analysis of Noninferiority Randomized Controlled Trials
Purpose: Proton pump inhibitors (PPIs) remain the standard treatment option for erosive esophagitis (EE) but have notable limitations due to side effects associated with long‐term use. Tegoprazan, a novel potassium‐competitive acid suppressant (P‐CAB), may provide an alternative treatment option. In this study, we aim to evaluate the healing rates of EE using tegoprazan versus PPIs, along with their respective safety profiles. Methods: A comprehensive literature search was conducted in PubMed, Embase, and ClinicalTrials.gov from inception to March 2025. Risk of bias was evaluated using the Cochrane RoB 2.0 tool. Pooled estimates were calculated using random‐effects models in Review Manager 5.4. Results: Three RCTs encompassing a total of 766 patients were included in the analysis. Tegoprazan demonstrated comparable healing rates to PPIs at both 4 weeks (risk ratio [RR] 1.05; 95% confidence interval [CI]: 0.99–1.11; p = 0.12) and 8 weeks (RR 1.02; 95% CI: 0.98–1.06; p = 0.35). Subgroup analyses by dose (50 and 100 mg) showed no significant differences. While overall adverse event rates were similar between groups, the incidence of headache was numerically lower in the tegoprazan group (1.3% vs. 4.2%; RR = 0.40; 95% CI: 0.08–2.00; p = 0.26), though this difference was not statistically significant. Conclusion: Tegoprazan shows comparable efficacy and safety to standard PPIs for treating EE. While healing rates were slightly higher, particularly with the 100 mg dose, the differences were not statistically significant. Tegoprazan may be a suitable alternative for patients intolerant to PPIs, though larger, long‐term, multiethnic studies are warranted to confirm these findings and assess patient‐centered outcomes.
- Open Access
- 17 July 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (6) , 1536-1549
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence
- 17 July 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (6) , 1536-1549
Open AccessObicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence